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We report the synthesis and the affinity data at both the peripheral (PBR) and the central
benzodiazepine receptors of a series of N,N-dialkyl-2-phenylindol-3-ylglyoxylamide derivatives
III, designed as conformationally constrained analogues of 2-phenylindole-3-acetamides II such
as FGIN-1-27. Most of the new compounds showed a high specificity and affinity for PBR,
with Ki in the nanomolar to subnanomolar range. The most potent ligands (4-7, 9, 13-27)
stimulated steroid biosynthesis in rat C6 glioma cells with a potency similar to or higher than
that of classical ligands. The SARs of this new class of compounds are discussed.
Introduction
Benzodiazepines (Bz) are among the most widely
prescribed drugs in the treatment of anxiety and sleep
disorders, eliciting their action by binding to an allo-
steric site located on the ç-aminobutyric acid-A (GABAA)
receptor complex, the central benzodiazepine receptor
(BzR).1 Since Bz cause several unwanted side effects,
an alternative approach to the identification of new
anxiolytics has recently focused on ligands acting at
other sites of the GABAA complex. Neurosteroids posi-
tively modulate GABA neurotransmission, eliciting
nonsedative anxiolytic effects beneficial for the memory,
learning, and emotional processes. In the central ner-
vous system their concentration is increased by ligands
at the peripheral benzodiazepine receptor (PBR) such
as PK 11195, alpidem, Ro5-4864, and FGIN-1-27 (Fig-
ure 1), which facilitate the rate-limiting transport of
cholesterol into mitochondria, where it is converted into
pregnenolone, the parent molecule of endogenous
steroids.2-5 Being involved for several years in the
search for new anxiolytics, we reported several indolyl-
glyoxylamides I (Figure 1) as BzR ligands provided by
agonist/partial agonist efficacy.6 It is worth noting the
structural similarity of indolylglyoxylamides I with the
2-arylindol-3-acetamides II such as FGIN-1-27 (Figure
1), reported by Kozikowski et al.5 as PBR selective high-
affinity ligands. Prompted by this observation, we
prepared and tested a series of N,N-dialkyl-2-phenylin-
dol-3-ylglyoxylamide derivatives III (Figure 1) designed
as conformationally constrained analogues of the in-
doleacetamides II that could hopefully exhibit higher
affinity at the PBR.
Chemistry
The intermediates for the synthesis of the N,N-
dialkyl-2-phenylindol-3-ylglyoxylamides 1-27 were the
2-arylindoles 32-37, of which 33 and 35-37 were
obtained through a modified Madelung indole synthesis7
(Scheme 1). The general procedure employed to prepare
1-27 involved the acylation of the 2-phenylindoles 32-
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Figure 1. Structures of PBR ligands and pharmacophore/
topological model.8
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37 with oxalyl chloride to give the corresponding in-
dolylglyoxylyl chlorides 38-43, which were allowed to
react with the appropriate amine in the presence of
triethylamine in dry toluene solution (Scheme 2).
Biological Studies
The binding affinity of the indolylglyoxylamides 1-27
at the PBR was determined in rat kidney membranes
by competition experiments against [3H]PK 11195. The
PBR/BzR selectivity of 1-27 was evaluated by binding
studies using membranes from rat brain tissues and
[3H]flumazenil as radioligand.
Furthermore, a subset of high-affinity compounds was
examined for their ability to stimulate pregnenolone
formation from rat C6 glioma cells. All experimental
details are given in Supporting Information.
Results and Discussion
Most of the compounds 1-27 showed a high affinity
for PBR in the nanomolar to subnanomolar range and
a high selectivity for PBR over BzR because they
inhibited the binding of [3H]flumazenil at rat brain
membranes to an extent varying from 0% to 16% at a
fixed 10 íM concentration (Table 1). Noticeably, the
indolylglyoxylamides displayed a gain in affinity values
Table 1. Receptor Binding Affinity of Compounds 1-27 for PBR, BzR, and Their Stimulatory Effects on Pregnenolone Biosynthesis
Ki (nM) or inhibition (%)
compd R1 R2 R3 R4 PBRa BzRb
increase of pregnenolone
production vs control (%)c
1 (CH2)2CH3 H H H 815 ( 80 3929 ( 381
2 (CH2)3CH3 H H H 1167 ( 99 12%
3 CH2CH3 CH2CH3 H H 43.0 ( 4 6%
4 (CH2)2CH3 (CH2)2CH3 H H 12.2 ( 1.0 16% 8 ( 1
5 (CH2)3CH3 (CH2)3CH3 H H 7.50 ( 0.7 3% 23 ( 3
6 (CH2)4CH3 (CH2)4CH3 H H 16.0 ( 2.0 3% 35 ( 4
7 (CH2)5CH3 (CH2)5CH3 H H 1.40 ( 0.2 10% 30 ( 3
8 CH(CH3)2 CH(CH3)2 H H 103 ( 9.0 4%
9 CH(CH3)CH2CH3 CH(CH3)CH2CH3 H H 17.0 ( 2.0 5% 10 ( 2
10 -(CH2)4- H H 2400 ( 125 4%
11 -(CH2)5- H H 665 ( 30 3%
12 -(CH2)6- H H 33.0 ( 3.0 5%
13 (CH2)2CH3 (CH2)2CH3 Cl H 4.65 ( 0.52 14% 40 ( 5
14 (CH2)3CH3 (CH2)3CH3 Cl H 1.00 ( 0.27 0% 55 ( 6
15 (CH2)5CH3 (CH2)5CH3 Cl H 0.55 ( 0.19 4% 109 ( 9
16 (CH2)2CH3 (CH2)2CH3 F H 4.28 ( 0.32 4% 20 ( 4
17 (CH2)3CH3 (CH2)3CH3 F H 2.40 ( 0.81 0% 26 ( 3
18 (CH2)5CH3 (CH2)5CH3 F H 0.37 ( 0.13 0% 62 ( 7
19 (CH2)2CH3 (CH2)2CH3 CH3 H 5.50 ( 0.38 7% 148 ( 12
20 (CH2)3CH3 (CH2)3CH3 CH3 H 3.80 ( 0.91 11% 58 ( 8
21 (CH2)5CH3 (CH2)5CH3 CH3 H 1.60 ( 0.13 6% 77 ( 9
22 (CH2)2CH3 (CH2)2CH3 H Cl 2.80 ( 0.3 10% 10 ( 2
23 (CH2)3CH3 (CH2)3CH3 H Cl 4.91 ( 0.4 13% 5 ( 1
24 (CH2)5CH3 (CH2)5CH3 H Cl 58.4 ( 6 3% 31 ( 3
25 (CH2)2CH3 (CH2)2CH3 Cl Cl 0.62 ( 0.06 5% 49 ( 6
26 (CH2)3CH3 (CH2)3CH3 Cl Cl 1.9 ( 0.2 0% 147 ( 13
27 (CH2)5CH3 (CH2)5CH3 Cl Cl 5.8 ( 0.6 3% 166 ( 12
PK 11195 9.3 ( 0.5 48 ( 5
Ro 5-4864 23 ( 3.1 41 ( 4
alpidem 0.5-7 1-28
a The concentration of tested compounds that inhibited [3H]PK11195 binding to rat kidney mitochondrial membranes (IC50) by 50%
was determined with six concentrations of the displacers, each performed in triplicate. Ki values are the mean ( SEM of three
determinations. b The inhibition percent of [3H]flumazenil specific binding at 10 íM of the compound are the mean ( SEM of five
determinations. Ki values are the mean ( SEM of three determinations. c C6 glioma cells were incubated for 2 h at 37 °C in the presence
of each compound. Pregnenolone was quantified by radioimmunoassay as described in the text. The values represent the mean ( SEM
of at least three determinations. For comparison, the effects of PK 11195 and Ro5-4864 on pregnenolone production are also included.
Scheme 1 Scheme 2
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of at least 1 order of magnitude with respect to their
2-phenylindole-3-acetamide counterparts II.5
SARs will be discussed in light of our pharmacophore/
topological model of the PBR binding site8 made up of
three lipophilic pockets (L1, L3, and L4) and a H-bond
donor group (H1) (see Figure 1).
Among the unsubstituted indolylglyoxylamides 1-12
(R3 ) R4 ) H), the least effective were the N-monosub-
stituted derivatives 1 and 2 probably because they
cannot occupy both the L3 and L4 lipophilic pockets.
Thus, we did not further examine this type of substitu-
tion.
The N,N-disubstituted derivatives 3-9 exhibited
nanomolar affinity because they fill both the L3 and L4
sites. Compound 7, bearing two n-hexyl groups, was the
most potent one, with a Ki of 1.4 nM. A progressive
enhancement of affinity was generally observed by
increasing the length of the linear N-alkyl groups (3-
7), due to the progressively better filling of both the L3
and L4 lipophilic pockets, with 6 being the only excep-
tion. Branching of the N,N-dialkyl groups (8 and 9) gave
mixed results. Compound 8 (Ki ) 103 nM) showed a
surprising drop in affinity if compared with its un-
branched counterpart 3 (Ki ) 43 nM), while product 9
maintained the affinity with respect to 4. This affinity
difference between 8 and 9 does not find any easy
rational explanation either from the point of view of the
lipophilicity or from that of the steric hindrance. In any
case, the affinity data of 3-9 suggest that interactions
at the L3 and L4 sites are governed primarily by
lipophilicity and that steric factors may also play some
role.
Also, in the subseries of the cyclic amides 10-12, the
affinity was enhanced with increasing dimensions of the
cycle. However, 10 and 11 showed a considerable drop
in affinity with respect to the linear derivatives 3 and
4 probably because of their incapability of optimally
filling both the L3 and L4 sites, which are separated in
the binding site, while the more lipophilic and flexible
12 displayed an appreciable affinity (Ki ) 33 nM), again
confirming the role of lipophilicity in the interaction of
these ligands with the receptor site.
The three most potent derivatives 4, 5, and 7 were
selected as leads for further affinity optimization efforts.
Insertion of the electron-donating lipophilic methyl
group in the 4′-position of the 2-phenyl ring (R3) left the
affinity nearly unchanged because 19-21 were equi-
potent with the parent compounds 4, 5, and 7. By in-
troducing an electron-withdrawing substituent such as
chlorine or fluorine into the 4′-position, we obtained 13-
15 or 16-18, respectively, which exhibited a gain in
affinity of 2.5-fold to 7.5-fold. Among them, the N,N-di-
n-hexyl derivative 18 stood out as the most potent of
all the ligands, with a Ki of 0.37 nM, similar to that of
alpidem. These results suggest that the phenyl ring of
2-phenylindoles might be involved in a ð-stacking
interaction with an electron-rich aromatic ring within
the L1 pocket and that this interaction is reinforced by
4′ electron-withdrawing substituents such as the halo-
gens.
In the 4′-phenyl-substituted indoles, potency cor-
related with the N-alkyl length: n-hexyl > n-butyl >
n-propyl. This affinity trend was reversed when a
chlorine was introduced in the 5-position of the indole
nucleus: the longer the side chains, the lower the
potency. Among the 5-chloro-4′-phenyl-unsubstituted
derivatives 22-24, the highest potency was exhibited
by 22 (Ki ) 2.8 nM), which bears two n-propyl groups
on the amide nitrogen. Insertion of a chlorine in both
the 5 and 4′ positions improved potency with respect to
the unsubstituted derivatives when the amide chain
featured n-propyl or n-butyl groups (compare 25 and 26
vs 4 and 5); otherwise, it was unfavorable (compare 27
vs 7, both bearing n-hexyl groups). In other words, the
effects on affinity of a chlorine in the 5 and 4′ positions
are not additive but depend on the nature of the N,N-
dialkyl chains. It is tempting to speculate that the
length of the 5,4′-dichloro-2-phenylindole scaffold within
the binding site restricts the mobility of the whole ligand
within the binding site. Under these steric constraints,
the L3 and L4 pockets are optimally filled by the smaller
n-propyl or n-butyl, compared with the bulkier n-hexyl
chains. To sum up, the lack of additive effects of
substituents NR1R2, R3, and R4 is somehow related to a
simultaneous increase in their dimensions, which makes
each single interaction at the three lipophilic sites less
effective.
The most potent indolylglyoxylamides (4-7, 9, 13-
27) were tested for their ability to increase pregnenolone
concentration in rat C6 glioma cells in comparison with
PK 11195 and Ro5-4864 (Table 1). Products 19, 26, and
27 proved to be highly effective in increasing preg-
nenolone production by more than 145% vs controls.
Several compounds (13, 14, 18, 20, 21, and 25) increased
pregnenolone accumulation with a potency similar to
or slightly higher than that of PK 11195 and Ro5-4864.
As a general trend, unsubstituted indolylglyoxylamides
(4-7, 9) did not produce a great effect on the preg-
nenolone level, whereas a better performance was
displayed by the 4′-substituted derivatives 13-21 and
25-27.
Experimental Section
Chemistry. General directions are in the Supporting
Information.
General Procedure for the Synthesis of N,N-Dialkyl-
[5-substituted-2-(4-substitutedphenyl)indol-3-yl]glyoxyl-
amide Derivatives 1-27. A solution of the appropriate amine
(2.75 mmol) in 50 mL of dry toluene was added dropwise to a
stirred suspension, at 0 °C, of chloride 38-43 (2.5 mmol) and
triethylamine (3.0 mmol) in 50 mL of the same solvent. The
reaction mixture was left to warm to room temperature, stirred
for 2-24 h (TLC analysis), and then filtered. In the case of
products 1 and 2, the precipitate was triturated with a
saturated NaHCO3 aqueous solution and washed with water
to give the first portion of crude product. The toluene solution
was washed with diluted HCl and then with a saturated
NaHCO3 aqueous solution and water, dried (MgSO4), and
evaporated to dryness to yield crude 3-27.
All products 1-27 were purified by recrystallization from
the appropriate solvent or by flash chromatography (eluting
system: petroleum benzine (60-80 °C) and ethyl acetate in
varying ratios). Yields, recrystallization solvents, melting
points, and spectral data are listed in Tables 1 and 2 in the
Supporting Information.
Supporting Information Available: General chemistry
directions, synthesis and physical properties of compounds 33
and 35-43, Tables 1 and 2 containing yields, recrystallization
solvents, melting points, the IR and 1H NMR spectral data of
1-27, and biological methods. This material is available free
of charge via the Internet at http://pubs.acs.org.
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